Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by NIZAR M TANNIR and PHEROZE TAMBOLI.
NIZAR M TANNIR
Connection Strength
2.316
PHEROZE TAMBOLI
  1. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
    View in: PubMed
    Score: 0.147
  2. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
    View in: PubMed
    Score: 0.134
  3. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct; 36(5):450-4.
    View in: PubMed
    Score: 0.115
  4. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9.
    View in: PubMed
    Score: 0.106
  5. Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall. Am J Surg Pathol. 2012 Apr; 36(4):583-8.
    View in: PubMed
    Score: 0.104
  6. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. 2011 May; 22(5):1048-1053.
    View in: PubMed
    Score: 0.095
  7. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010 Nov 15; 116(22):5219-25.
    View in: PubMed
    Score: 0.094
  8. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010 Jan 01; 116(1):57-65.
    View in: PubMed
    Score: 0.089
  9. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 01; 27(25):4076-81.
    View in: PubMed
    Score: 0.086
  10. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008 Apr 22; 98(8):1336-41.
    View in: PubMed
    Score: 0.079
  11. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021 12; 19(6):e401-e408.
    View in: PubMed
    Score: 0.050
  12. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 11; 32(11):1698-1707.
    View in: PubMed
    Score: 0.043
  13. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017 Dec 15; 123(24):4823-4831.
    View in: PubMed
    Score: 0.038
  14. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res. 2017 Nov 01; 23(21):6686-6696.
    View in: PubMed
    Score: 0.037
  15. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist. 2017 03; 22(3):286-292.
    View in: PubMed
    Score: 0.036
  16. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
    View in: PubMed
    Score: 0.036
  17. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792.
    View in: PubMed
    Score: 0.036
  18. Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. Cancer Immunol Res. 2016 10; 4(10):820-822.
    View in: PubMed
    Score: 0.035
  19. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clin Cancer Res. 2016 Dec 15; 22(24):6236-6246.
    View in: PubMed
    Score: 0.035
  20. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84.
    View in: PubMed
    Score: 0.034
  21. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol. 2016 08; 70(2):348-57.
    View in: PubMed
    Score: 0.034
  22. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26.
    View in: PubMed
    Score: 0.034
  23. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016 05; 35(21):2687-97.
    View in: PubMed
    Score: 0.033
  24. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2015 Oct; 1(4):212-24.
    View in: PubMed
    Score: 0.033
  25. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5.
    View in: PubMed
    Score: 0.033
  26. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35.
    View in: PubMed
    Score: 0.033
  27. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene. 2016 Mar 24; 35(12):1565-74.
    View in: PubMed
    Score: 0.032
  28. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29.
    View in: PubMed
    Score: 0.032
  29. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23.
    View in: PubMed
    Score: 0.032
  30. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. 2015 Aug; 194(2):316-22.
    View in: PubMed
    Score: 0.032
  31. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9.
    View in: PubMed
    Score: 0.032
  32. Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma: report of a case with unusual morphology and clinical follow-up. Chin J Cancer. 2014 Jul; 33(7):351-5.
    View in: PubMed
    Score: 0.030
  33. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014 Jul; 192(1):36-42.
    View in: PubMed
    Score: 0.030
  34. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. 2014 Nov; 66(5):874-80.
    View in: PubMed
    Score: 0.030
  35. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res. 2013 Sep 01; 19(17):4673-84.
    View in: PubMed
    Score: 0.028
  36. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol. 2013 May; 63(5):947-52.
    View in: PubMed
    Score: 0.027
  37. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One. 2012; 7(8):e42324.
    View in: PubMed
    Score: 0.027
  38. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int. 2012 Dec; 110(11):1742-6.
    View in: PubMed
    Score: 0.026
  39. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011 Dec; 60(6):1273-9.
    View in: PubMed
    Score: 0.025
  40. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011 Nov; 60(5):964-71.
    View in: PubMed
    Score: 0.024
  41. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol. 2011 Jan; 42(1):146-50.
    View in: PubMed
    Score: 0.024
  42. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011 Jan; 59(1):10-5.
    View in: PubMed
    Score: 0.023
  43. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol. 2010 Nov; 184(5):1877-81.
    View in: PubMed
    Score: 0.023
  44. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010 Jul 15; 116(14):3378-88.
    View in: PubMed
    Score: 0.023
  45. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol. 2010 Aug; 21(8):1599-1606.
    View in: PubMed
    Score: 0.022
  46. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer. 2009 Nov 15; 125(10):2342-8.
    View in: PubMed
    Score: 0.022
  47. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics. 2009 May-Jun; 29(3):741-54; discussion 755-7.
    View in: PubMed
    Score: 0.021
  48. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):801-7.
    View in: PubMed
    Score: 0.021
  49. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology. 2009 Feb; 73(2):337-41.
    View in: PubMed
    Score: 0.021
  50. Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am J Roentgenol. 2008 Oct; 191(4):1220-32.
    View in: PubMed
    Score: 0.020
  51. Multisystem crisis in a patient with presumptive renal cell carcinoma. Clin Genitourin Cancer. 2008 Sep; 6(2):128-30.
    View in: PubMed
    Score: 0.020
  52. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008 Jul; 180(1):94-8.
    View in: PubMed
    Score: 0.020
  53. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol. 2007 Nov; 178(5):1896-900.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.